Astrazeneca Stock News

Pune, March 17, 2022 (GLOBE NEWSWIRE) -- Global Oncology/Cancer Drugs market research report gives an insight of worldwide business analysis with top players operating in the industry and future competitive scenario. The Oncology/Cancer Drugs market report made by our experts is completely great research which includes the growth of Oncology/Cancer Drugs, shares, revenue in past and future possibilities with consideration of challenges and opportunities. Also, the report includes detailed segmentation based on product type, application, geographical regions, countries with possible development and risks in these areas. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20416395 The global Oncology/Cancer Drugs market was valued at 8436.95 Million USD in 2021 and will grow with a CAGR of 4.34% from 2021 to 2027, based on Researcher''s newly published report. The topmost companies in the Oncology/Cancer Drugs market are commonly focused on innovative opportunities associated with the invention and supply of Oncology/Cancer Drugs.

Britain''s medicines regulator said on Thursday it had approved AstraZeneca''s antibody-based COVID-19 treatment for patients with poor immune response, marking a major step in the fight against the pandemic.

AstraZeneca PLC (LSE:AZN) is set to pay out US$775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation rela

Results from a phase 3 trial demonstrated an improvement in overall survival compared to placebo in patients taking AstraZeneca (AZN) and Mercks Lynparza for breast cancer.

There are reasons to like Amgen that go beyond its market-beating 3.4% dividend yield.

Phoenix, AZ, March 16, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced the opening of a new Phase 0/1b clinical trial to evaluate AZD1390, an Ataxia telangiectasia mutant (ATM) kinase inhibitor being developed by AstraZeneca, in patients with recurrent grade IV gliomas. The study will accrue up to 21 participants with a recurrent glioma who require re-radiation. The goal of this open-label, single-center Phase 0/1b study composed of a Phase 0 and an expansion Phase 1b, is to confirm blood-brain barrier penetration of AZD1390 and explore whether it increases the efficacy of radiation therapy. Patients with tumors demonstrating a positive pharmacokinetics (PK) response in the Phase 0 portion of study will graduate to the expansion Phase 1b, which combines therapeutic dosing of AZD1390 with standard of care fractionated radiotherapy. "This study of AZD1390 builds on our investigation of agents that enhance the effect of radiation treatment.

European Medicines Agency has started reviewing AstraZeneca Plc''s (NASDAQ: AZN ) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion . Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily … Full story available on Benzinga.com

Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival

A committee of the the European Medicines Agency has begun reviewing AstraZeneca''s (AZN) application for COVID-19 therapy Evusheld, Reuters reported.The EMA''s Committee for…

AstraZeneca PLC (LSE:AZN)'s application for Evusheld, an antibody-based Coronavirus (COVID-19) therapy is being reviewed by the European Medicines Agency, in an important step towards approval by the

Viatris (VTRS) shares are trading marginally higher in the post-market Tuesday after the U.S

Could health care stocks be the top picks in the stock market this week?

The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical

AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.

The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical